ReviewFrontiers in immunology2026
Incision-triggered neuroimmune remodeling of nociceptor ion channels: from postoperative inflammation to pain chronification.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic postsurgical pain (CPSP) arises after a known tissue insult, yet no intervention reliably prevents its development. This Review examines whether incision-triggered inflammation remodels nociceptor voltage-gated ion channels in ways that sustain peripheral input and favor pain chronification. We integrate human genetic and clinical evidence, incision-specific perturbation studies, functional work in non-surgical models, and expression-level associations distinguishing mechanistic strength from directness to CPSP. We focus on NaV1.7, NaV1.8, NaV1.9, and CaV3.2 within a broader network that includes peripheral transducing channels whose gating, trafficking, and abundance can be altered by TNF-α, IL-1β, IL-6, chemokines, p38 MAPK, NF-κB, and gp130/JAK signaling. Direct incision evidence now includes antisense and pharmacologic studies linking TNF-α/p38/NF-κB signaling to NaV1.8 and NaV1.9 expression and acute hypersensitivity, as well as single-cell maps showing insult-specific macrophage and neutrophil programs and protective immune-derived signals. Evidence from rare channelopathies does not establish population-level CPSP susceptibility. However, no human study has demonstrated the complete sequence from a defined postoperative immune signal to altered channel function and persistent pain. Sex, age, and hormonal context are plausible modifiers, but the strongest mechanistic evidence remains model-dependent and preclinical. Selective NaV1.8 inhibition validates peripheral channel tractability for acute pain but not prevention of CPSP. We therefore propose a testable, evidence-calibrated framework in which pathogenic and resolving immune programs act across peripheral, ganglion, and spinal compartments, and we define the experiments, biomarkers, and target-time-population alignment needed to determine whether this framework can guide mechanism-based prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.